- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The Top 5 Q&As of 2023
Pharm Exec spent the year speaking with some of the most interesting professionals from the life sciences industry.
Q&A: How Does a ‘Never Enough’ Achievement Culture Impact Your Workforce’s Morale? Planning for 2024 With Journalist and Author Jennifer Breheny Wallace
Jennifer Breheny Wallace, award-winning journalist and author, notes that C-Suite leaders should understand the financial risks of not taking action to address workplace burnout in 2024.
Reacting to Trends: Q&A With Leslie Orne, CEO of Trinity Life Sciences
Orne discusses the forces impacting the life sciences market and how companies are reacting.
Q&A With Kevin O'Neill, president and CEO of GE HealthCare, Pharmaceutical Diagnostics
O'Neill discusses the company's place in the global market and recent advancements to improve the patient experience.
The Changing Prescriber Communications Dynamic: Q&A with Caleb Costa, Chief Customer Officer at InCrowd
Explore the changing dynamics of healthcare professionals' communication preferences in a post-pandemic world, as Pharm Exec's Fran Pollaro has a no frills discussion about InCrowd's latest insights with chief customer officer Caleb Costa.
Threads, the Twitter Competitor's Impact on Pharma Marketing: Q&A with Justin Chase
An insightful discussion about how Meta's newest social media platform, Threads, is quickly adding another facet to the digital landscape for pharma marketers.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
